Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

I. Rini, Brian; R. Plimack, Elizabeth; Stus, V.P.; Gafanov, Rustem; D. Hawkins, Robert; Nosov, Dmitry; Pouliot, Frédéric; Yа. Alekseev, B.; Soulières, Denis; Melichar, Bohuslav; Vynnychenko, Ihor; Kryzhanivska, Anna; Bondarenko, Igor; Jobim Azevedo, Sérgio; Borchiellini, Delphine; Szczylik, Cezary; Markus, Maurice; S. McDermott, Raymond; Bedke, Jens; Tartas, Sophie; Chang, Yen‐Hwa; Tamada, Satoshi; Shou, Qiong; F. Perini, Rodolfo; Chen, Mei; B. Atkins, Michael; Powles, Thomas

doi:10.1056/nejmoa1816714

Public

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Published in New England Journal of Medicine • Feb 16, 2019

Authors:

Brian I. Rini

Elizabeth R. Plimack

V.P. Stus

Abstract

BACKGROUND: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. METHODS...

Subject

Axitinib

Sunitinib

Pembrolizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!